Oncologic photodynamic therapy photosensitizers: a clinical review.

By R. Allison, C. Sibata. Photodiagnosis and Photodynamic Therapy, 2010

754 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Ophthalmology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/041df2b85b3ac79278e3c7193ca93030d4610b0f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomedical Engineering

1. Michael R Hamblin
2. Zhaochu Yang
3. Tao Dong
4. Brian C. Wilson
5. David B. Graves

In Pulmonary and Respiratory Medicine

1. Michael R Hamblin
2. Brian C. Wilson
3. David B. Graves

Citations in the corpus

• Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions (2017, background): “Several properties are generally accepted as ideal [21,124].”
• PHOTODYNAMIC THERAPY OF CANCER: AN UPDATE (2011, background): “Other pertinent desirable properties of PS agents have been summarized elsewhere.(6) Although the interval between drug administration and irradiation is usually long, so that the sensitizer is given sufficient time to diffuse from normal tissues, reports now suggest that the tumor response may be s”
• Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions (2021, background): “Light absorption is mainly due to endogenous chromophores existing in tissues, such as hemoglobin, myoglobin, and cytochromes, which can reduce the photodynamic process by competing with PS in the absorption process [44,45].”